Melissa Rhodes
Chief Operating OfficerDr. Melissa Rhodes, PhD, DABT, is Chief Operating Officer of Avalyn Pharma Inc. from September 2023. Dr. Rhodes served in various roles at Kriya Therapeutics, Inc. from February 2020 to July 2023, most recently as President & Chief Development Officer, Metabolic Diseases & Neurology. Dr. Rhodes had been Chief Development Officer at Aerami Therapeutics (formerly known as Dance Biopharm Holdings, Inc.). since February 4, 2019 until February 2020. Dr. Rhodes has firsthand drug development and biotechnology industry experience including almost a decade at GlaxoSmithKline. Most recently, she held the position of Chief Development Officer at Altavant Sciences, where she was responsible for project leadership of clinical assets, as well as translational medicine, chemistry manufacturing and controls, regulatory affairs and project management. Previously, Melissa served as Senior Vice President at Roivant Sciences, Inc. where she managed all aspects of nonclinical research. Dr. Rhodes completed her Ph.D. at Duke University, focusing on pharmacology and toxicology and is a Diplomate of the American Board of Toxicology and received a B.S. from North Carolina State University.
Positions
- Company NameAvalyn Pharma Inc.Stock CodeAVLNPositionChief Operating OfficerColleagues
- LBLyn BaranowskiCEO, President & Director
- HDHeather D. TurnerIndependent Chairman
- DRDouglas R. CarlsonCFO & Chief Business Officer
- HMHoward M. LazarusChief Medical Officer
- CSCassie SaitowSenior Director of IR & Corporate Communications
- JCJill CarrollIndependent Director
- EMErin M. LavelleIndependent Director
- KHKathryn HavilandIndependent Director
